JMJosep Martí

Josep Martí

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Josep Martí has a total of 205 co-authors. Here are the top co-authors by number of shared publications:

  • Constantino Fondevila

    Hepatopancreatobiliary Surgery & Transplantation, General & Digestive Surgery Service Hospital Universitario La Paz, Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Madrid, Spain

    12 shared publications
  • Joana Ferrer

    Hepatobiliopancreatic Surgery and Liver and Pancreatic Transplantation Unit, Department of Surgery, Clinical Institute of Digestive and Metabolic Diseases (ICMDiM), Hospital Clínic Barcelona, Spain

    11 shared publications
  • Josep Fuster

    Liver Surgery & Transplantation Unit, Department of Surgery, ICMDM, Hospital Clinic, IDIBAPS, CIBERehd, Villarroel, 170, 08036, Barcelona, Spain

    9 shared publications
  • Juan Carlos García-Valdecasas

    Liver Surgery and Transplant Unit, Department of Surgery, Institut de Malalties Digestives i Metabòliques Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain

    7 shared publications
  • Ramon Charco

    Vall d'Hebron Barcelona Hospital Campus, Spain

    7 shared publications
  • Amalia Pelegrina

    Liver Surgery and Transplant Unit, Department of Surgery, Institut de Malalties Digestives i Metabòliques Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain

    5 shared publications

Latest Publications

  • Analysis of Preoperative Portal Vein Embolization Outcomes in Patients with Hepatocellular Carcinoma: A Single-Center Experience

    by Josep Marti, Massimo Giacca, Kutaiba Alshebeeb, Sumeet Bahl, Charles Hua, Jeremy C. Horn, Jad BouAyache, Rahul Patel, Marcelo Facciuto, Myron Schwartz, et al.


  • Open Access

    Changes of liver hemodynamic and elastography parameters in patients with colorectal liver metastases receiving preoperative chemotherapy: “a note of caution”

    by Amalia Pelegrina, Josep Martí, Rosa Miquel, Joana Ferrer, Virginia Hernández-Gea, Alba Diaz, Cristina Nadal, Juan Carlos García-Valdecasas, Josep Fuster

    New systemic chemotherapy agents have improved prognosis in patients with colorectal liver metastases (CLM), but some of them damage the liver parenchyma and ultimately increase postoperative morbidity and mortality after liver resection. The aims of our study were to determine the degree of hemodynamic and pathological liver injury in CLM patients receiving preoperative chemotherapy and to identify an association between these injuries and postoperative complications after liver resection. This is a prospective descriptive study of patients with CLM receiving preoperative chemotherapy before curative liver resection from November 2013 to June 2014. All patients had preoperative elastography and hepatic hemodynamic evaluation. We analyzed clinical preoperative data and postoperative outcomes after grouping the patients by chemotherapy type, development of sinusoidal obstructive syndrome (SOS), and development of major complications. Eleven from the 20 patients included in the study received preoperative oxaliplatin-based chemotherapy (OBC). Nine patients had SOS at pathological analysis and five patients developed major complications. Patients receiving preoperative OBC had higher values of hepatic venous pressure gradient (HVPG) and developed more SOS and major complications. Patients developing SOS had higher values of HVPG and developed more major complications. Patients with major complications had higher values of HVPG, and patients with a HVPG of 5 mmHg or greater had more major complications than those under 5 mmHg (20 vs 80%, p = 0.005). OBC and SOS impair liver hemodynamics in CLM patients. An increase in major complications after liver resection in these patients develops at subclinical HVPG levels.


  • Letter in reply: Prognostic prediction by liver tissue proteomic profiling in patients with colorectal liver metastases

    by Adalgiza Reyes, Josep Marti, Santiago Marfa, Wladimiro Jimenez, Vedrana Reichenbach, Amalia Pelegrina, Constantino Fondevila, Juan Cg Valdecasas, Josep Fuster

    In response to: S Sabour. Prognostic prediction by liver tissue proteomic profiling in patients with colorectal liver metastases; rule of thumb.

  • Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil

    by Delia D'AVola, Valentín Cuervas‐Mons, Josep Martí, Jorge Ortiz de Urbina, Laura Lladó, Carlos Jimenez, Esteban Otero, Francisco Suarez, Juan M. Rodrigo, Miguel‐Angel Gómez, et al.

    Cardiovascular (CV) diseases are recognized longterm causes of death after liver transplantation (LT). The objective of this multicenter study was to analyze the prevalence and the evolution of CV risk factors and CV morbidity and mortality in 1819 LT recipients along 5 years after LT. The influence of baseline variables on survival, morbidity, and mortality was studied. There was a continuous and significant increase of the prevalence of all the CV risk factors (except smoking) after LT. CV diseases were the fourth cause of mortality in the 5 years after LT, causing 12% of deaths during the follow‐up. Most CV events (39%) occurred in the first year after LT. Preexisting CV risk factors such as age, pre‐LT CV events, diabetes, metabolic syndrome, and hyperuricemia, and mycophenolate‐free immunosuppressive therapy, increased post‐LT CV morbidity and mortality. The development of new‐onset CV risk factors after LT, such as dyslipidemia and obesity, independently affected late CV morbidity and mortality. Tacrolimus and steroids increased the risk of posttransplant diabetes, whereas cyclosporine increased the risk of arterial hypertension, dyslipidemia, and metabolic syndrome. In conclusion, CV complications and CV mortality are frequent in LT recipients. Preexisting CV risk factors, immunosuppressive drugs, but also the early new onset of obesity and dyslipidemia after LT play an important role on late CV complications. A strict metabolic control in the immediate post‐LT period is advisable for improving CV risk of LT recipients. Liver Transplantation 23 498–509 2017 AASLD.


  • Prognostic Prediction by Liver Tissue Proteomic Profiling in Patients with Colorectal Liver Metastases

    by Adalgiza Reyes, Josep Marti, Santiago Marfà, Wladimiro Jiménez, Vedrana Reichenbach, Amalia Pelegrina, Constantino Fondevila, Juan Carlos Garcia Valdecasas, Josep Fuster

    To obtain proteomic profiles in patients with colorectal liver metastases (CRLM) and identify the relationship between profiles and the prognosis of CRLM patients. Prognosis prediction (favorable or unfavorable according to Fong's score) by a classification and regression tree algorithm of surface-enhanced laser desorption/ionization TOF-MS proteomic profiles from cryopreserved CRLM (patients) and normal liver tissue (controls). The protein peak 7371 m/z showed the clearest differences between CRLM and control groups (94.1% sensitivity, 100% specificity, p < 0.001). The algorithm that best differentiated favorable and unfavorable groups combined 2970 and 2871 m/z protein peaks (100% sensitivity, 90% specificity). Proteomic profiling in liver samples using classification and regression tree algorithms is a promising technique to differentiate healthy subjects from CRLM patients and to classify the severity of CRLM patients.


  • Open Access

    Metastatic Tissue Proteomic Profiling Predicts 5-Year Outcomes in Patients with Colorectal Liver Metastases

    by Santiago Marfà, Josep Marti, Adalgiza Reyes, Gregori Casals, Guillermo Fernández-Varo, Silvia Carvajal, J.C. García-Valdecasas, Josep Fuster, Wladimiro Jiménez


  • Top Cited Papers
    Open Access

    Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment

    by G. Sapisochin, M. Facciuto, L. Rubbia‐Brandt, J. Marti, N. Mehta, F.Y. Yao, E. Vibert, D. Cherqui, D.R. Grant, R. Hernandez‐Alejandro, et al.

    The presence of an intrahepatic cholangiocarcinoma (iCCA) in a cirrhotic liver is a contraindication for liver transplantation in most centers worldwide. Recent investigations have shown that “very early” iCCA (single tumors ≤2 cm) may have acceptable results after liver transplantation. This study further evaluates this finding in a larger international multicenter cohort. The study group was composed of those patients who were transplanted for hepatocellular carcinoma or decompensated cirrhosis and found to have an iCCA at explant pathology. Patients were divided into those with “very early” iCCA and those with “advanced” disease (single tumor >2 cm or multifocal disease). Between January 2000 and December 2013, 81 patients were found to have an iCCA at explant; 33 had separate nodules of iCCA and hepatocellular carcinoma, and 48 had only iCCA (study group). Within the study group, 15/48 (31%) constituted the “very early” iCCA group and 33/48 (69%) the “advanced” group. There were no significant differences between groups in preoperative characteristics. At explant, the median size of the largest tumor was larger in the “advanced” group (3.1 [2.5‐4.4] versus 1.6 [1.5‐1.8]). After a median follow‐up of 35 (13.5‐76.4) months, the 1‐year, 3‐year, and 5‐year cumulative risks of recurrence were, respectively, 7%, 18%, and 18% in the very early iCCA group versus 30%, 47%, and 61% in the advanced iCCA group, P = 0.01. The 1‐year, 3‐year, and 5‐year actuarial survival rates were, respectively, 93%, 84%, and 65% in the very early iCCA group versus 79%, 50%, and 45% in the advanced iCCA group, P = 0.02. Conclusion: Patients with cirrhosis and very early iCCA may become candidates for liver transplantation; a prospective multicenter clinical trial is needed to further confirm these results. (Hepatology 2016;64:1178‐1188)


  • Open Access

    Surgical management of noncirrhotic portal hypertension

    by Josep Marti, Ganesh Gunasekaran, Kishore Iyer, Myron Schwartz


  • Calcified Telangiectatic Hyperplastic Nodule Associated With Vascular Malformation in a Child: A Case Report

    by Josep Marti, Anshu Trivedi, Valentina D'Alessandro, Sasan Roayaie, Ally Rosen, Ronen Arnon, Swan Thung

    This is a case report of an asymptomatic 4-year-old girl who was found to have a nodule at the lateral left lobe of the liver. She underwent transabdominal liver ultrasound and abdominal MRI that showed calcification and intense arterial enhancement but they failed to clearly exclude malignancy. The patient underwent an unremarkable laparoscopic wedge liver resection of the lesion because of its location and size. Pathological examination showed features compatible with a benign telangiectatic hyperplastic nodule with vascular malformation and calcification. CD34 immunostained the proliferative vascular lining cells while CK7 and CK19 highlighted the normal bile ducts present within the lesion. The diagnosis of a telangiectatic hyperplastic nodule associated with vascular malformation has been scarcely reported in children and our case shows for the first time that it can also present with calcifications.


  • Differences in Surgical Outcomes Between Hepatitis B- and Hepatitis C–Related Hepatocellular Carcinoma

    by Bernardo Franssen, Kutaiba Alshebeeb, Parissa Tabrizian, Josep Marti, Elisa S. Pierobon, Nir Lubezky, Sasan Roayaie, Sander Florman, Myron E. Schwartz

    Compare surgical outcomes for hepatitis B virus (HBV)-hepatocellular carcinoma (HCC) versus hepatitis C virus (HCV)-hepatocellular carcinoma (HCC). HCC is the second leading cause of death from cancer worldwide and is associated with hepatitis virus infection in 80% of cases. Between 1997 and 2011, 1008 patients with hepatitis B (HBV, n = 431) or hepatitis C (HCV, n = 577) underwent resection (n = 567) or transplantation (n = 441). Resection was indicated for Child's A patients with single HCC; transplantation was indicated for patients within Milan criteria. Univariate and multivariate analyses were performed as well as survival and recurrence analysis using log-rank test. Based on uniform application of these criteria, resection: transplantation ratio was 3.6 for patients with HBV and 0.67 for patients with HCV. Resection: Patients with HBV had larger tumors and higher α-fetoprotein but less satellites and macrovascular invasion; 68% of HBV versus 89% of HCV were cirrhotic. Survival was better (P < 0.001) and recurrence was lower (P = 0.009) for HBV. Independent predictors of death included HCV (P = 0.024), transfusion (P = 0.013), and HCC of greater than 5 cm (P = 0.013). Limiting analysis to patients with cirrhosis, survival with HBV remained superior (P = 0.020) but recurrence did not. Transplantation: Tumors were similar in HBV and HCV. Survival was better (P = 0.002) for HBV; recurrence was similar. Independent predictors of death were HCV (P < 0.001), poor differentiation (P = 0.049), vascular invasion (P = 0.002), and outside Milan (P = 0.032). Limiting analysis to patients within Milan, HBV survival remained better for both resection (P = 0.030) and transplantation (P = 0.002). Survival after both resection and transplantation for HCC was better in HBV- than in HCV-related HCC whereas recurrence was also lower for HBV-HCC in the resection group, these differences are influenced by both liver and tumor factors.